(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 September 2012 (13.09.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/120125 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/EP2012/054144

(22) International Filing Date:
9 March 2012 (09.03.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

1103955.9	9 March 2011 (09.03.2011)	GB
61/450,896	9 March 2011 (09.03.2011)	US

(71) Applicant *(for all designated States except US)*: **ANTITOPE LTD** [GB/GB]; Babraham Research Campus, Babraham, Cambridge Cambridgeshire CB22 3AT (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **JONES, Timothy David** [GB/GB]; 27 Brick Row, Babraham, Cambridge Cambridgeshire CB22 3AJ (GB). **HOLGATE, Robert George Edward** [GB/GB]; 96 Princes Mews, Royston Hertfordshire SG8 9BL (GB). **CARR, Francis Joseph** [GB/GB]; Birchlea, The Holdings, Balmedie Aberdeenshire AB23 8WU (GB).

(74) Agent: **CHAPMAN, Paul William**; 20 Red Lion Street, London Greater London WC1R 4PJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2012/120125 A1

(54) **Title**: HUMANISED ANTI CTLA-4 ANTIBODIES

Figure 1:



(57) **Abstract**: The invention provides an anti-CTLA4 antibody which inhibits the binding of CTLA4 to human B7,in particular,it inhibits binding of CTLA4 to human B7.1 and/or human B7.2. Specific antibodies are provided with specific variable region sequences as well as compositions comprising such antibodies for use in treating disease.

HUMANISED ANTI-CTLA4 ANTIBODIES

The present invention relates to the treatment and prevention of human diseases using novel humanised antibodies against human CTLA4 and methods of treating or preventing human diseases using these antibodies.

BACKGROUND TO THE INVENTION

The vertebrate immune system requires multiple molecular and cellular interactions to achieve optimal immune responses. In particular, activation of T lymphocytes (T cells) is an important component of many such responses. Antigen-presenting cells (APC) can activate T cells by presentation of antigens via peptides carried by major histocompatibility complex (MHC) molecules to the TCR (T cell receptor). Such activation also requires co-stimulation by APC. Delivery of a non-specific costimulatory signal to T cell requires at least two homologous B7 family members found on APC, B7-1 (also called B7, B7.1, or CD80) and B7-2 (also called B7.2 or CD86), both of which can deliver costimulatory signals on binding to the CD28 antigen on T cells resulting in T cell activation. CD28 is a homodimeric glycoprotein member of the immunoglobulin (Ig) superfamily with a single extracellular variable region, and is present on most mature human T cells.

A homologue of CD28 named CTLA4 (Cytotoxic Lymphocyte Associated Antigen, also designated CD152) was discovered in 1987 (Brunet et al., (1987) Nature 328:267-270) with particular association with cytotoxic T cells. As with CD28, CTLA4 is a member of the Ig superfamily and comprises a single extracellular Ig domain. However, the role of CTLA4 is primarily to inhibit T cell activation and this was shown in CTLA4 deficient mice (Chambers et al., (1997) Immunity. 7:8855-8959) which suffer from massive lymphoproliferation. In addition, blockage of CTLA4 was shown to enhance T cell responses in vitro (Walunas et al., (1994)) Immunity. 1:405-413 and in vivo (Kearney (1995) J. Immunol. 155:1032-1036) and also to increase antitumour immunity (Leach (1996) Science. 271:1734-1736). Therefore, blockage of

CTLA4 might provide new treatments for disease, especially human diseases where immune stimulation might be beneficial such as for treatment of cancers and infectious diseases.

Development of blockers of CTLA4 function has focused on the use of monoclonal antibodies, especially antibodies derived from transgenic mice engrafted with genes encoding human immunoglobulins (and deficient in host mouse immunoglobulin genes). Clinical trials are ongoing with such antibodies including Ipilimumab (Keler et al., J Immunol 171:6251-6259(2003)), which is an IgG1 isotype, and Tremelimumab (Ribas et al., Oncologist 12: 873-883(2005)) which is an IgG2 isotype. Whilst the immunogenicity (induction of antibodies against the injected human monoclonal antibodies) is generally reported to be low, there is concern that such human antibodies, due to somatic mutations and rearrangements in the variable region sequences (which may result in T cell epitopes), may induce immunogenicity in some patients resulting in adverse effects and lack of therapeutic effect. There is thus a need for improved anti-CTLA4 monoclonal antibodies with a potentially lower immunogenicity in order to provide more effective treatments of human diseases.

SUMMARY OF THE INVENTION

The present invention relates to novel humanised antibodies which specifically bind to human CTLA4. The invention also provides humanised antibodies where binding to human CTLA4 inhibits the binding of human CTLA4 to human B7. The invention also provides humanised antibodies that bind to human CTLA4 with an equilibrium dissociation constant (Kd) of at least 10^{-8}M. The invention also provides humanised antibodies that specifically bind to human CTLA4 that block binding of human CTLA4 to human B7 by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%. The invention also provides humanised antibodies that specifically bind to human CTLA4 having an antibody heavy chain of either isotype IgG1, IgG2, IgG3 or IgG4, or having a mutated IgG constant region, for example to inhibit binding to Fc receptors or to inhibit binding to complement. The invention also

provides humanised antibodies wherein the antibody light chain is a kappa light chain. The humanised antibody can be encoded by human IgG heavy chain and human kappa light chain nucleic acids that encode protein sequences in their variable regions as set forth in SEQ ID NO:31 through SEQ ID NO:50. In a preferred embodiment of the present invention, the humanised antibody comprises variable regions from SEQ ID NO:45 and SEQ ID NO:49 (otherwise referred to as "VH5:VK4').

The present invention also provides humanised antibodies that specifically bind to human CTLA4 whereby the antibody variable regions have been selected or modified to exclude one or more human CD4+ T cell epitopes. The present invention also provides human antibodies that specifically bind to human CTLA4 whereby the antibody variable regions have been formed primarily by fusing segments of sequences from existing human antibody variable region sequences.

The present invention also provides humanised antibodies of the invention comprising heavy chain CDR1, CDR2, and CDR3 amino acid sequences, "DYNMD" (SEQ ID No.9), "NINPNSESTSYNQKFKG" (SEQ ID No.10) and "DGNRYDAWFAY" (SEQ ID No. 11), respectively, and light chain CDR1, CDR2, and CDR3 amino acid sequences, "SASSSVTYMH" (SEQ ID No.12), "STSILAS" (SEQ ID No.13), and "QQRTSYPLT" (SEQ ID No. 14), respectively.

The present invention also provides humanised antibodies of the invention comprising heavy chain CDR1, CDR2, and CDR3 amino acid sequences, "SYWIN" (SEQ ID No.15), "RIAPGSGTTYYNEVFKG" (SEQ ID No.16) and "GDYGSY" (SEQ ID No.17), respectively, and light chain CDR1, CDR2, and CDR3 amino acid sequences, "SASSSISYMH" (SEQ ID No.18), "DTSKLAS" (SEQ ID No.19), and "HQRTSYPLT" (SEQ ID No.20), respectively.

Humanised antibodies of the present invention can be composed of any of the above CDR sequences SEQ ID No.9 to SEQ ID No.20 and minor variants of these CDR

sequences where alterations of one or more amino acids does not significantly alter binding to human CTLA4. Humanised antibodies can be created by joining together the CDR sequences with sequences from human variable region frameworks where such framework sequences are derived from single or multiple other human antibody variable region framework sequences. Commonly such human variable region framework sequences will include one or more mutations which contribute to optimal or improved binding of the humanised antibodies to CTLA4. In a preferred embodiment of the present invention, such human variable region framework sequences in the humanised antibodies are derived entirely from sequences in other human antibody variable regions as described in methods of EP1844074 (Antitope Ltd). These sequences comprise joined segments of sequences from other human antibody variable regions, together with human constant regions. In particular, such humanised antibodies also contain CDR sequences derived from CDR sequences, framework sequences or part framework/CDR sequences from other human antibody variable regions together with human constant regions, thus creating humanised antibodies in which the variable region sequences are derived entirely from sequences in other human antibody variable regions together with human constant regions, thus creating a "fully human" antibody.

The invention also provides humanised antibodies that specifically bind to human CTLA4, wherein said humanised antibody is produced by a mammalian cell line, especially CHO or NS0 cells. The invention also provides a humanised antibody that specifically binds to human CTLA4 that is a Fab fragment or a single chain Fv (scFv). The invention also provides multispecific antibodies (two or more different antibody molecules joined together to give two or more different specifities) including at least one humanised antibody from the sequences SEQ ID NOS:31 to 35 for the heavy chain and SEQ ID NOS:36 to 40 for the light chain for antibody 3B10; or humanised antibody from the sequences SEQ ID NOS:41 to 45 for the heavy chain and SEQ ID NOS:46 to 50 for the light chain for the antibody 8H5, each of which specifically binds to human CTLA4. In a preferred embodiment, the invention provides

multispecific antibodies with variable regions consisting of SEQ ID NOS:45 for the heavy chain and SEQ ID NOS:49 for the light chain. The different antibodies included in each multispecific antibody can be linked to each other either covalently or non-covalently.

The invention provides a pharmaceutical composition comprising a humanised antibody that specifically binds to human CTLA4 and a pharmaceutically acceptable carrier. The pharmaceutical composition can further comprise an agent effective to induce an immune response against a target antigen, or one or more chemotherapeutic agents.

The invention provides a method for inducing, augmenting or prolonging an immune response to an antigen in a patient, comprising administering to the patient an effective dosage of a humanised antibody that specifically binds to human CTLA4, wherein the antibody blocks binding of human CTLA4 to human B7. The antigen can include a tumour antigen, an antigen associated with a pathogen, an antigen associated with a disease of the central nervous system (CNS), an antigen associated with diseases of the blood system including hypertension and atherosclerosis, an antigen associated with an inflammatory disease including rheumatoid arthritis and autoimmune diseases, or an antigen associated with an allergy. Tumour antigens can be one or more antigens on the cell surface of a tumour, one or more molecules which interact with the tumour, one or more MHC complexes of peptides derived from tumour antigens, or antigens not directly associated with tumours but where immune responses to the antigen will have an adverse effect on the tumour such as antigens associated with the tumour vasculature. Pathogens can be a virus, a bacterium, a fungus or a parasite. CNS antigens include beta amyloid associated with plaque deposits in Alzheimer's disease. Blood system antigens include integrins and adhesins, as well as antigens associated with plaque deposits in atherosclerosis. Inflammatory disease antigens include cytokines and cytokine receptors. Allergy antigens include antigens associated with food, plant, chemical and environmental allergens. The method of the invention can

also include administering the antigen, or a fragment or an analogue thereof, to the patient, whereby the antigen in combination with the humanised antibody induces, augments or prolongs the immune response.

The invention also provides a method of suppressing an immune response in a patient, comprising administering to the patient an effective dosage of a multivalent preparation comprising at least two humanised antibodies to human CTLA4 linked to each other resulting, for example, in the induction of regulatory T cells or the down regulation of CTLA4. The invention also provides a method of suppressing an immune response in a patient, comprising administering to the patient an effective dosage of a polyclonal preparation comprising at least two humanised antibodies to human CTLA4.

The present invention further provides humanised monoclonal antibodies which specifically bind to human CTLA4, as well as compositions containing one or a combination of such antibodies. Some of the humanised antibodies of the invention are characterised by binding to human CTLA4 with high affinity, and/or by blocking the interaction of human CTLA4 with its ligand, the human B7-1 and B7-2 molecules. Accordingly, such humanised antibodies of the invention can be used as diagnostic or therapeutic agents in vivo and in vitro.

The humanised antibodies of the invention can encompass various antibody isotypes, or mixtures thereof, such as IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE or mutated forms of these IgGs such as mutations which reduce of eliminate binding to Fc receptors. Typically, they include IgG4 (e.g. IgG4k) and IgG1 (e.g. IgG1k). The humanised antibodies can be full-length (e.g., an IgG4 or IgG1 antibody) or can include only an antigen-binding portion (e.g., a Fab, F(ab')2, Fv or a scFv fragment).

Some humanised anti-CTLA4 antibodies of the present invention can be characterised

by one or more of the following properties: a) specificity for human CTLA4 (specifically binding to human CTLA4); b) a binding affinity to human CTLA4 with an equilibrium dissociation constant (Kd) of at least 10^{-8}M.

In another aspect, the invention provides nucleic acid molecules encoding the humanised antibodies, or antigen-binding portions, of the invention. Accordingly, recombinant expression vectors that include the antibody-encoding nucleic acids of the invention, and host cells transfected with such vectors, are also encompassed by the invention, as are methods of making the antibodies of the invention by culturing these host cells.

Anti-human CTLA4 humanised monoclonal antibodies of the invention, or antigen binding portions thereof (e.g., Fab), can be derivatised or linked to another functional molecule, e.g., another peptide or protein (e.g., a Fab' fragment). For example, an antibody or antigen-binding portion of the humanised antibodies of the invention can be functionally linked (e.g., by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities. For example, the humanised anti-CTLA4 antibody, or antigen binding fragment thereof, can be conjugated to a therapeutic moiety, e.g., a cytotoxic drug, an enzymatically active toxin, or a fragment thereof, a radioisotope, a therapeutic nucleic acid, or a small molecule anti-cancer drug. The antibodies of the invention can also be conjugated to cytotoxic pharmaceuticals, e.g., radiolabeled with a cytotoxic agents such as, e.g. 131I, or can be coupled to a ribosome inactivating protein, e.g. pseudomonas exotoxin (PE38 fragment, plant or bacterial toxins such as ricin, the α-chain of ricin, saporin, pokeweed antiviral protein, diphtheria toxin, or *Pseudomonas* exotoxin A (Kreitman and Pastan (1998) *Adv. Drug Delivery Rev. 31*:53.).

In another aspect, the present invention provides compositions, e.g., pharmaceutical and diagnostic compositions, comprising a pharmaceutically acceptable carrier and at

least one humanised monoclonal antibody of the invention, or an antigen-binding portion thereof, which specifically binds to human CTLA4. Some compositions may also comprise a combination of the humanised antibodies or antigen-binding portions of the invention. Such compositions may also comprise combinations with one or more other biologically active molecules as separate molecules, for example, a combination of at least one humanised monoclonal antibody of the invention and another biologically active molecule, or may combine combinations with one or more other biologically active molecules in the same molecule, for example as a bispecific or multispecific molecule either as a combination of two or more humanised antibodies of the invention or as a combination with one or more other biologically active molecules.

For *in vivo* methods, the antibody, or antigen-binding portion thereof (or a bispecific or multispecific molecule of the invention), can be administered to a human subject suffering from a T-cell-related disease, or a disease that can be ameliorated or prevented by inducing, augmenting, prolonging or suppressing an immune response.

Humanised monoclonal antibody compositions of the invention also can be administered in combination with other known therapies, e.g., an anti-cancer therapy. Accordingly, the invention provides a method for treating cancer in a subject comprising administering a therapeutically effective amount of a pharmaceutical composition of a humanised antibody together with a pharmaceutical carrier to the subject. Some such methods include combination with a vaccine. Some such vaccines include a tumour cell vaccine, a GM-CSF-modified tumour cell vaccine, a nucleic acid (such as DNA) vaccine, and a tumour-associated antigen or an antigen-loaded dendritic cell vaccine.

Humanised antibodies to human CTLA4 can be used in methods of treatment requiring either stimulation of immune responses or suppression. Stimulation is achieved using antibodies that block binding of human CTLA4 to human B7 and

diseases amenable to treatment by stimulation and augmentation of prolonging of immune responses include cancers of the prostate, kidney, colon, lung or breast; pathogenic infections; diseases associated with the CNS e.g. amyloidogenic diseases including Alzheimer's disease; and diseases with inflammatory or allergic components. Immunosuppression can also be achieved using humanised antibodies to human CTLA4, for example through induction of regulatory T cells (Coquerelle et al., *Gut* 2009;58:1363-1373). Diseases amenable to treatment include graft versus host disease, host versus graft disease, allergy, autoimmune diseases and other inflammatory diseases.

In yet another aspect, the present invention provides a method using antibodies of the invention for detecting in vitro or in vivo the presence of human CTLA4 antigen in a sample, e.g., for diagnosing a human CTLA4-related disease. In some methods, this is achieved by contacting a sample to be tested, along with a control sample, with a humanised monoclonal antibody of the invention, or an antigen-binding portion thereof (or a bispecific or multispecific molecule), under conditions that allow for formation of a complex between the antibody and human CTLA4. Complex formation is then detected (e.g., by ELISA) in the test samples, and any statistically significant increase in the formation of complexes between the test and control samples is indicative the presence of human CTLA4 antigen in the test sample.

It will be understood by those skilled in the art that the humanised antibodies of the present invention will have additional uses or compositions beyond those described herein, in all cases where the humanised antibody binds to human CTLA4 antigen whereby such uses and compositions shall be considered to be within the scope of the invention. It will be understood by those skilled in the art that the variable region sequences of the humanised antibodies of the present invention (SEQ ID NO:31 through SEQ ID NO:50) or CDRs of the humanised antibodies of the present invention (SEQ ID NO:9 through SEQ ID NO:20) may be subject to variations which do not significantly change the properties of the humanised antibodies of the present

invention whereby such variants shall be considered to be within the scope of the invention. In addition, such variations either within the variable region or CDR sequences of the humanised antibodies should be considered to be within the scope of the present invention where the variable region sequences of such variants have significant homology to the humanised sequences of the present invention. For example, a variant nucleic acid may be determined to be within the scope of the invention where this includes sequences containing or substantially identical to SEQ ID NO:21 through SEQ ID NO:30 as determined by its ability to hybridise under stringent conditions to a nucleic acid of the present invention. In one embodiment, a nucleic acid sequence can be determined to be within the scope of the invention (e.g., is substantially identical to SEQ ID NO:21 through SEQ ID NO:30) by its ability to hybridise under stringent conditions to a nucleic acid within the scope of the invention (such as SEQ ID NO:21 through SEQ ID NO:30). The term "hybridise" refers to the binding, duplexing, or hybridising of a molecule to a particular nucleotide sequence under stringent hybridisation conditions when that sequence is present in a complex mixture (e.g. total cellular or library DNA or RNA), wherein the particular nucleotide sequence is detected at least at about 10 times background. Stringent hybridisation conditions will be selected, for example, to be 5-10°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH.

EXAMPLES

The following examples shall not be considered as limiting to the scope of the invention. The figures and tables relate to the examples below and are as follows;

Figure 1 – binding of murine antibodies to CTLA4-Fc.

Figure 2 – competition ELISA of murine antibodies for binding to CTLA4-Fc against biotinylated B7.1.

Figure 3 - competition ELISA of murine antibodies for binding to CTLA4-Fc against biotinylated B7.2.

Figure 4 – binding of chimeric 3B10 and 8H5 human IgG1 antibodies to CTLA4-Fc.

Figure 5 - competition ELISA of chimeric 3B10 and 8H5 human IgG1 antibodies for binding to CTLA4-Fc against biotinylated B7.1.

Figure 6 - competition ELISA of chimeric 3B10 and 8H5 human IgG1 antibodies for binding to CTLA4-Fc against biotinylated B7.2.

Figure 7 – T cell proliferation of human PBMC in response to chimeric 3B10 and 8H5 human IgG1 antibodies.

Figure 8 – pANT antibody expression vector maps.

Figure 9 – 3B10 variable region (VH and VK) DNA sequences.

Figure 10 – 8H5 VH and VK DNA sequences.

Figure 11 - 3B10 VH and VK amino acid sequences.

Figure 12 – 8H5 VH and VK amino acid sequences.

Figure 13 – Humanised 3B10 VH amino acid sequences.

Figure 14 – Humanised 3B10 VK amino acid sequences.

Figure 15 – Humanised 8H5 VH amino acid sequences.

Figure 16 – Humanised 8H5 VK amino acid sequences.

Figure 17 - Competition ELISA of humanised 8H5 antibodies for binding to CTLA4-Fc against biotinylated chimeric 8H5 human IgG1 (="h8H5 parent IgG1").

Figure 18 – IFNχ secretion by lead humanised VH5/VK4 anti-CTLA4 and MDX0101 in a human mixed lymphocyte reaction with donor pairs.

Figure 19 – Growth of MC38 tumour in human CTLA4 knock-in mice with weekly antibody doses starting at Day 2.

Table 1 – Primer sequences for amplification of murine cDNA variable regions.

Table 2 - Primer sequences for amplification of murine variable regions for cloning into pANT17 and pANT13.

Commercially available reagents referred to in the Examples were used according to manufacturer's instructions unless otherwise indicated. The source of cells identified in the Examples and throughout the specification by ECACC accession numbers is the European Collection of Cell Cultures (ECACC), Salisbury, England. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Exemplary methods and materials are described below although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention. The materials, methods, and examples are illustrative only and not intended to be limiting in scope.

EXAMPLE 1 - GENERATION OF MOUSE MONOCLONAL ANTIBODIES

Recombinant CTLA4-fusion protein comprising the extracellular domain of human CTLA4 fused to the human IgG1 constant domain was purchased from R&D Systems (Oxford, UK). Extracellular CTLA4 fragment was prepared by proteolytic cleavage of the CTLA4-Fc fusion protein with Factor Xa (Qiagen, Crawley, UK) followed by subsequent removal of the protease using Factor Xa removal resin (Qiagen) and of the cleaved Fc fragment using Protein A-agarose to leave the CTLA4 extracellular domain only.

Female Balb/c mice were immunised subcutaneously with 200ul of a 1:1 emulsion of Freunds Complete Adjuvant (Sigma-Aldrich, Dorset, UK) containing 20ug of CTLA4-Fc fusion protein. Immunised mice were subsequently boosted approximately every 3 weeks with up to three intraperitoneal injections of a 1:1 emulsion of Freunds Incomplete Adjuvant (Sigma-Aldrich) containing 20ug of CTLA4-Fc. 3 days prior to myeloma fusion, the two mice showing the highest antibody titre received an intrasplenic boost of either whole antigen or CTLA4 extracellular domain.

Spleens were extracted and homogenised to yield a single cell suspension. $1x10^8$ spleen cells were fused with 5 $x10^7$ NS0 mouse myeloma cells (2:1 ratio) using polyethylene glycol (PEG). The fused cells were resuspended in 200ml of DMEM / 20% FCS / 5% BM Condimed H1 (Roche, Burgess Hill, UK) containing the hybridoma selection agents azaserine and hypoxanthine – "HAZA medium" and pipetted in 200ul volumes into 10 x 96 well plates. Plates were incubated at 37°C in 5% CO_2 and one half volume (100ul) of each culture well was replaced every other day with fresh HAZA medium containing 2.5% BM Condimed H1. After 12 days incubation, 100ul of spent medium from each growth well were transferred to a 96 well storage plate and tested for the presence of secreted anti-CTLA4-fusion protein antibodies using the CTLA4-fusion protein ELISA as described below. Immunopositive cultures were expanded by transferring to 1ml of "H-medium"

(DMEM / 20% FCS / hypoxanthine) in a 24 well plate and growth allowed to proceed for 5 - 7 days. Positive cultures were then subcloned by limiting dilution, expanded and tested by CTLA4-fusion protein ELISA. In addition, positive cultures were tested by FACS as described below.

For limiting dilution, cells counts were determined using a haemocytometer and cells diluted serially in medium containing 2.5% BM Condimed H1 until cell densities of 5 to 15 cells/ml were achieved. For each hybridoma, 200ul of cell solution was pipetted into 48 wells with a density of 1 to 3 cells per well. Cultures were maintained at 37°C in 5% CO_2 for 2 weeks with an additional medium feed of half a volume after 1 week. Culture medium was tested for the presence of antibodies specific for anti-CTLA4-fusion protein by ELISA. ELISA positive clones were selected and expanded to 10ml cultures in DMEM / 20% FCS / 2.5% BM Condimed H1. Clones were then frozen in medium containing 10% DMSO and stored in liquid N2, and also expanded further for antibody purification. Two hybridomas designated 3B10 and 8H5 were subcloned and subclones were then frozen and used for monoclonal antibody production in further studies.

To identify hybridomas secreting anti-human CTLA4-specific mouse antibodies, ELISA plates (VWR, Lutterworth, UK) were coated overnight at 4°C with 100ul/well of either recombinant CTLA4 fusion protein or human IgG1 (Sigma-Aldrich, Poole, UK) at 0.5µg/ml in PBS. Plates were washed and blocked with 150ul/well PBS containing 2% BSA. Cell culture supernatants or purified antibodies were diluted in PBS/2% BSA and 100ul added to each plate followed by incubation for 1 hour at room temperature. Plates were washed three times with PBS-Tween (0.05%) and incubated for 1 hour with 100ul/well goat anti-mouse Ig (Fab-specific) conjugated to Horseradish Peroxidase (Sigma-Aldrich). Plates were washed three times with PBS-Tween following which SigmaFast OPD substrate (Sigma-Aldrich) was added and incubated at room temperature in the dark for 4 minutes. The reaction was stopped by

adding 50 µl of 3M HCl. Plates were read at 490nm using a Dynex plate reader (Dynex, Worthing, UK).

Monoclonal antibodies were isotyped using the Rapid ELISA Mouse Antibody Isotyping Kit (Perbio, Cramlington, UK). Antibodies were purified on a 1ml Protein A-sepharose column (GE Healthcare, Little Chalfont, UK). Prior to purification, both the tubing and the Protein A column were depyrogenated using 0.4M NaOH. The column was re-equilibrated with 20 CV of 1x PBS pH 7.4. Hybridoma cell culture supernatants were harvested, adjusted to 1x PBS pH 7.4 using 10x PBS and filter sterilised. Filtered supernatant was pumped through the column at 0.5 ml/min. The column was washed with 1x PBS pH 7.4 and IgG was eluted using sterile 0.1M Sodium Citrate pH3, with 0.9 ml fractions collected and neutralised with 0.1ml of sterile 1M Tris-HCl pH 9. Under sterile conditions, the product was buffer exchanged into PBS pH 7.4 to remove any elution buffer and concentrate the sample. After concentration, antibodies were quantified by OD280nm using an extinction coefficient, Ec (0.1%) of 1.4. Purified antibodies were analysed by SDS-PAGE using a Novex NuPAGE electrophoresis system with 4-12% NuPage gel (Invitrogen, Paisley, UK) and MES running buffer. 1 µg of antibody was prepared with 4xNuPAGE sample buffer plus beta-mercaptoethanol and heated. The gel was stained with InstantBlue staining solution (Expedeon, Cambridge, UK) and molecular size were estimated by comparing stained bands to PageRuler™ Plus Prestained Protein Ladder (Fermentas, York, UK). Two bands were identified for each antibody with no detectable contamination present.

In order to evaluate binding of antibodies to CTLA4 and blocking of the interaction between CTLA4 with CTLA4 ligands B7.1 and B7.2, competition assays were performed by ELISA. The ligands B7.1-Ig and B7.2-Ig (R&D Systems) were biotinylated using Biotin Tag™ Micro Biotinylation kit (Sigma–Aldrich). 96 well MaxiSorp plates (Nunc) were coated with 0.5µg/ml recombinant human CTLA4-Ig (IgG1) (R&D Systems) in Dulbecco's PBS (PAA Laboratories, Yeovil, UK) (80µl

final volume) at 4°C overnight. CTLA4-Ig was discarded and plates were blocked with Dulbecco's PBS-2%BSA for 1 hour at room temperature. Plates were washed 3 times with wash buffer (0.05% Tween20 in Dulbecco's-PBS). Test antibodies at various concentrations were premixed with either biotinylated-B7.1-Ig (0.36µg/ml final concentration) or biotinylated-B7.2-Ig (0.65µg/ml final concentration) and then added to the CTLA4-Ig plate (80µl final volume). All samples were tested in duplicate. Plates were incubated 1h at room temperature and washed 3 times with wash buffer. 80µl of a 1 in 500 dilution of Streptavidin HRP (Sigma-Aldrich) was added and incubated for 1 hour at room temperature. Plates were washed 3 times with wash buffer and 80µl of SigmaFast OPD substrate (Sigma-Aldrich, Cat# P9187) was added and incubated at room temperature in the dark for 4 minutes. The reaction was stopped by adding 50 µl of 3M HCl. Plates were read at 490nm using Dynex plate reader. Subclones 8H5-1B1, 3B10-4F7, 7B9-1A3 and 2C7-1G10 were selected as producers of lead monoclonal antibodies based on binding to CTLA4 (Figure 1). Of these leads, all but 7B9-1A3 were shown to compete with biotinylated B7.1 (Figure 2) and biotinylated B7.2 (Figure 3) for binding to human CTLA4.

In order to determine whether the lead monoclonal antibodies bound to CTLA4 expressed on the surface of T-cells, a flow cytometric analysis was performed. Human peripheral T cells were isolated from human PBMC (peripheral blood mononuclear cells) and stimulated to enhance expression of CTLA4. CD4+ cells were purified from PBMC using a $CD4^+$ T Cell Isolation Kit (Miltenyi Biotec, Bisley, UK), plated out in a 24 well plate ($1x10^6$ cells/well) in AIM-V Medium (Invitrogen, Paisley, UK) and incubated at 37°C overnight. Cells were stimulated with Ionomycin (1µg/ml) and PMA (phorbol 12-myristate 13-acetate) (50ng/ml) and incubated 4h at 37°C. Cells were washed once in AIM-V medium, fixed in PBS containing 2% formaldehyde for 15 min, and resuspended in FACS buffer (D-PBS containing 1%BSA, 0.05% sodium azide and 0.1% Saponin) at $2x10^6$cells/ml and incubated 30 min at 4°C.

$2x10^5$ cells were stained using either a 1 in 10 dilution of anti-CTLA4-PE conjugated antibody (BNI3) (Abcam, Cambridge, UK) as a positive control or with 5µg/ml of individual anti-CTLA4 monoclonal antibodies together with a 1 in 50 dilution of anti-mouse IgG-PE conjugated antibody (Sigma). Mouse IgG (Sigma) was also included as separate controls for the different murine isotypes present within the lead monoclonal antibodies. Cells were stained for 1 hour at 4°C. An anti-mouse IgG-PE conjugated antibody only control was also included. Cells were washed twice with FACS buffer and optionally stained for 1h in the dark at 4°C with either a 1 in 40 dilution of mouse anti-human CD4-FITC conjugated antibody (Caltag, Buckingham, UK) or mouse IgG2a-FITC conjugated antibody (Caltag). After two washes with FACS buffer, cells were resuspended in FACS buffer and flow cytometry performed using a Beckton Dickinson FACSCalibur (Becton Dickinson, Oxford, UK). Instrument settings were determined by analysis of relevant isotype control antibodies. Based on the observed binding to CTLA4, monoclonal antibodies 8H5 and 3B10 were designated as primary and secondary lead monoclonal antibodies respectively.

EXAMPLE 2 – VARIABLE REGION GENE SEQUENCING

Subclones 3B10-4F7, 3B10-6E3, 8H5-1A1 and 8H5-1B1 producing the lead monoclonal antibodies 8H5 and 3B10 were subjected to variable region (V-region) sequence analysis. Total RNA was extracted from 3 to $10x10^6$ hybridoma cells using the RNAqueous-4PCR Kit (Ambion, Warrington, UK) and used to synthesis cDNA. Murine immunoglobulin heavy and kappa light chain V-region fragments were amplified by PCR using degenerate mouse leader sequence primers (Sigma) and unique constant domain primers (Sigma) as shown in Table 1. The resulting PCR fragments were subcloned into the pGEM-T Easy I vector system (Promega, Southampton, UK) and inserts were sequenced using the vector-specific primer, M13Forward (Sigma) All DNA sequencing was performed by Geneservice Ltd, Cambridge, UK. Unique V-region nucleotide sequences were obtained for 3B10 (SEQ ID Nos 1 and 2) and 8H5 (SEQ ID Nos 5 and 6).

Sequences of 3B10 and 8H5 hypervariable regions (CDRs) were determined as follows;

SEQ ID No. 9 3B10 CDRH1 DYNMD
SEQ ID No. 10 3B10 CDRH2 NINPNSESTSYNQKFKG
SEQ ID No. 11 3B10 CDRH3 DGNRYDAWFAY
SEQ ID No. 12 3B10 CDRL1 SASSSVTYMH
SEQ ID No. 13 3B10 CDRL2 STSILAS
SEQ ID No. 14 3B10 CDRL3 QQRTSYPLT

SEQ ID No. 15 8H5 CDRH1 SYWIN
SEQ ID No. 16 8H5 CDRH2 RIAPGSGTTYYNEVFKG
SEQ ID No. 17 8H5 CDRH3 GDYGSY
SEQ ID No. 18 8H5 CDRL1 SASSSISYMH
SEQ ID No. 19 8H5 CDRL2 DTSKLAS
SEQ ID No. 20 8H5 CDRL3 HQRTSYPLT

EXAMPLE 3 – GENERATION OF CHIMERIC ANTIBODIES

The heavy and light chain variable domain sequences of the lead 3B10 and 8H5 monoclonal antibodies were PCR amplified and subcloned into pANT antibody expression vectors (Figure 8) with heavy and light chain V-regions cloned into pANT17 and pANT13 respectively. Heavy chain V-region genes were cloned into pANT17 via MluI and HindIII sites in frame with either the human γ1 heavy chain gene (G1m3 (G1m(f)) allotype) or the human γ4 heavy chain gene, and light chain V-region genes were cloned into pANT13 via BssHII and BamHI sites in frame with the human kappa light chain constant region gene (Km3 allotype). Transcription of both heavy and light chain genes was under the control of the CMV I/E promoter (US5168062 and US5385839, University of Iowa) and the pANT17 plasmid contained a mutant *dhfr* minigene (Simonsen & Levinson 1983, PNAS **80**:2495-2499) under the

control of a SV40 promoter and polyA sequence for selection in eukaryotic cells. Both pANT17 and pANT13 contained a β-lactamase (Ap^R) gene for prokaryotic selection and a pMB1 origin of replication for propagation in prokaryotic cells. All plasmids were propagated in *E. coli* XL1-blue (Stratagene Cat. No. 200130). Primers used to amplify the V-region genes for cloning into the pANT expression vectors are shown in Table 2.

The heavy and light chain expression constructs were then co-transfected either transiently into HEK293 cells by calcium phosphate-based transfection or stably transfected into NS0 cells by electroporation. Secreted antibody was purified from the cell culture supernatants by Protein A chromatography. By analysis with CTLA4 binding ELISA (Figure 4), CTLA4 competition ELISA against B7.1 and B7.2 (Figures 5 and 6), and by binding to CTLA4 expressed on T cells by flow cytometry as in Example 1, both 3B10 and 8H5 chimeric antibodies were shown to retain the CTLA4 binding of the starting monoclonal antibodies.

EXAMPLE 4 – T-CELL PROLIFERATION ASSAY

PBMC (peripheral blood mononuclear cells) were activated using beads coated with anti-human CD2, anti-human CD3 and anti-human CD28 antibodies (Miltenyi Biotec, Bisley, Surrey). $5x10^5$ cells were plated out into each well of a 96-well plate in AIM-V medium with beads added to cells at a ratio of 1 bead per cell. Test or isotype control antibodies were diluted as appropriate in AIM-V medium and 50µl per well added to the cells, giving a final volume of 200µl. Medium only (no antibody) controls were also included. Plates were incubated for 4 days at 37°C and cells were then pulsed with 0.75µCi [3H]-Thymidine (Perkin Elmer, Beaconsfield, UK) in AIM-V® culture medium and incubated for a further 18 hours before harvesting onto filter mats (Perkin Elmer) using a TomTec Mach III (Hamden CT, USA) cell harvester. Counts per minute (cpm) for each well were determined by Meltilex™ (Perkin Elmer) scintillation counting on a 1450 Microbeta Wallac Trilux Liquid Scintillation Counter

(Perkin Elmer) in paralux, low background counting. Counts per minute for each antibody sample were normalised to the medium-only control. In two separate studies, chimeric antibodies were shown to reverse the CTLA4-induced inhibition of T cell proliferation as seen with the starting monoclonal antibodies (Figure 7).

EXAMPLE 5 – GENERATION OF HUMANISED ANTIBODIES

Humanised antibodies were generated using methods described in EP1844074 (Antitope Ltd). Structural models of the mouse V-regions were produced using Swiss PDB and analysed in order to identify important amino acids from the 3B10 and 8H5 V-regions that were likely to be important for the CTLA4 binding properties of the antibody ('constraining residues'). A database of human V-region sequences was used to identify segments of human V-region sequences containing each of the constraining residues to be used in design of the humanised antibodies. Typically two or more alternative V-region sequence segments were used to provide each constraining residue resulting in a large range of possible sequences of humanised anti-CTLA4 V-region sequences for both 8H5 and 3B10. These sequences were then analysed for the prediction of non-germline MHC class II peptide binding by *in silico* analysis as described in Fothergill et al. (WO9859244, Eclagen Ltd) and also for known CD4+ T-cell epitopes using databases including "The Immune Epitope Database and Analysis Resource", http://www.immuneepitope.org/. V-region sequences with predicted non-germline MHC class II binding peptides or with significant hits against T cell epitope databases were discarded. This resulted in a reduced set of V-region sequences. Selected combinations of V-region sequence segments were then combined to produce humanised heavy and light chain variable region amino acid sequences. Five heavy chains and five light chain sequences (designated VH1 to VH5, and VK1 to VK5 respectively) were selected for each of 8H5 (SEQ ID Nos 41 to 45 and 46 to 50 respectively) and 3B10 (SEQ ID Nos 31 to 35 and 36 to 40 respectively).

DNA encoding humanised variant V-regions was synthesised and subcloned into the expression vectors pANT17 and pANT13 as described in Example 3. All

combinations of humanised VH and VK chains (i.e. a total of 25 pairings for each of 8H5 and 3B10) were transiently transfected into HEK293 and also transfected into NS0 cells, and antibody was purified by protein A chromatography from the culture supernatants as described in Example 3.

EXAMPLE 6 – ANALYSIS OF HUMANISED ANTIBODIES

The binding of HEK-derived and NS0-derived 8H5 and 3B10 humanised variants to recombinant CTLA4 was assessed in a competition ELISA against the appropriate parent chimeric antibody. The parental 8H5 and 3B10 chimeric antibodies were biotinylated using Biotin Tag™ Micro Biotinylation kit (Sigma–Aldrich). 96 well MaxiSorp plates (Nunc) were coated with 0.5µg/ml recombinant human CTLA4-Ig in Dulbecco's PBS (100µl final volume) at 4°C overnight. CTLA4-Ig was discarded and plates were blocked with Dulbecco's PBS-2%BSA for 1 hour at room temperature. Plates were washed 3 times with wash buffer (0.05% Tween20 in Dulbecco's-PBS). Test humanised antibodies at various concentrations were premixed with biotinylated parent chimeric antibody (0.02µg/ml final concentration) and then added to the CTLA4-Ig plate (100µl final volume). All samples were tested in duplicate. Plates were incubated for 1h at room temperature and washed 3 times with wash buffer. 100µl of a 1 in 500 dilution of Streptavidin HRP (Sigma-Aldrich) was added and incubated for 1 hour at room temperature. Plates were washed 3 times with wash buffer and 100µl of SigmaFast OPD substrate (Sigma-Aldrich, Cat# P9187) was added and incubated at room temperature in the dark for 4 minutes. The reaction was stopped by adding 50 µl of 3M HCl. Plates were read at 490nm using Dynex plate reader.

All lead 8H5 humanised variants displayed competitive binding profiles similar to the 8H5 chimeric antibody although variants containing the kappa chain VK5 showed slightly decreased binding compared to other variants (Figure 17). Similarly all lead humanised 3B10 variants displayed competitive binding profiles similar to the 3B10 chimeric antibody. In addition, all lead humanised 8H5 and 3B10 variants, when

tested in the CTLA4 competition ELISA against B7.1 and B7.2 (Example 3) gave very similar competitive binding profiles to the chimeric antibody shown in Figures 5 and 6 whereby >90% of B7.1 or B7.2 binding was inhibited at the maximum concentrations of the lead humanised variants. A lead humanised variant VH5/VK4 (SEQ ID Nos 45 and 39 respectively) was chosen as the lead antibody for further studies.

EXAMPLE 7 – GENERATION OF scFv's and Fab's

Humanised 8H5 and 3B10 variants from Example 6 were converted into scFv's and cloned into M13 phage display vectors as described in Benhar I. and Reiter Y., Current Protocols in Immunology, Unit 10.19B, Wiley Online Library, May 2002 (http://www.currentprotocols.com/protocol/im1019b) using the pCANTAB5E vector RPAS Expression Module (Amersham Pharmacia Biotech, Little Chalfont, UK). Humanised VH and VK genes were amplified using primers which provided terminal SfiI and NotI restriction sites, an internal Gly4Ser linker and a C terminal his6 tag. The scFv constructs were inserted into the pCANTAB5E vector as SfiI-NotI fragments and transformed into E.coli HB2151 resulting in scFv exported to the periplasm and partially to the growth medium. scFv's were purified from growth medium by nickel-chelate affinity chromatography using HIS-Select HF Cartridges (Sigma-Aldrich). Purified scFv's were tested in B7.1-Ig and B7.2-Ig competition assay as detailed in Example 1 and all humanised scFvs exhibited competitive binding to CTLA4. Humanised 8H5 and 3B10 variants from Example 6 were also converted into Fab's using the method used for scFv's except that amplified humanised VH and VK genes were further amplified with CH1 and Cκ constant region genes to form VH-CH1 and VK-Cκ fragments which were further amplified with primers to join these fragments with a 22 amino acid pelB leader sequence (Lei S.P., Lin H.C., Wang S.S., Callaway J., and Wilcox G., J Bacteriol. 169 (1987) p4379–4383) between the upstream VH-CH1 and downstream VK- Cκ gene fragments resulting in a dicistronic Fab gene. Fab's from humanised antibody variants were generated and purified as

above for scFv's and tested in B7.1-Ig and B7.2-Ig competition assay as detailed in Example 1. All humanised Fab's exhibited competitive binding to CTLA4.

EXAMPLE 8 – ANALYSIS OF CD4+ T CELL RESPONSES

PBMCs were isolated from healthy community donor buffy coats (from blood drawn within 24 hours) obtained from the UK National Blood Transfusion Service (Addenbrooke's Hospital, Cambridge, UK) and according to approval granted by Addenbrooke's Hospital Local Research Ethics Committee. PBMCs were isolated from buffy coats by Lymphoprep (Axis-shield, Dundee, UK) density centrifugation and $CD8^+$ T cells were depleted using $CD8^+$ RosetteSep™ (StemCell Technologies Inc, London, UK). Donors were characterised by identifying HLA-DR haplotypes using an HLA SSP-PCR based tissue-typing kit (Biotest, Solihull, UK). T cell responses to control antigens including the recall antigen tetanus toxin were also determined (KLH Pierce, Cramlingtom, UK and peptides derived from Influenza A and Epstein Barr viruses). PBMC were then frozen and stored in liquid nitrogen until required.

To prepare monocyte derived dendritic cells (DC), 50 different donor PBMCs were selected to provide a distribution with frequencies of HLA-DR and HLA-DQ allotypes similar to the frequencies in the overall world population. PBMCs were revived in AIM-V® culture medium and $CD14^+$ cells isolated using Miltenyi CD14 Microbeads and LS columns (Miltenyi Biotech, Oxford, UK). Monocytes were resuspended in AIM-V® supplemented with 1000U/ml IL-4 and 1000U/ml GM-CSF ("DC culture medium") to 4-6x10^6 PBMC/ml and then distributed in 24 well plates (2ml final culture volume). Cells were fed on day 2 by half volume DC culture medium change. By day 3, monocytes had differentiated to semi-mature DC which were pre-incubated with either 40ug/ml of test humanised or chimeric antibody, 100µg/ml KLH or medium only. Semi-mature DC were incubated with antigen for 24 hours after which excess test antibody was removed by washing the cells twice and resuspending in DC culture medium supplemented with 50ng/ml TNF-α (Peprotech, London, UK). DCs

were fed on day 7 by a half volume DC culture medium (supplemented with 50ng/ml TNFα) change before harvesting mature DC on day 8. The harvested mature DC were counted and viability assessed using trypan blue dye exclusion. The DC were then γ-irradiated (4000 rads) and resuspended at $2x10^5$ cells per ml in AIM-V medium before use in the ELISpot and proliferation assays. Additionally, on day 8, fresh CD4+ T cells were also prepared. To purify CD4+ T cells, PBMCs were revived in AIM-V® culture medium and $CD4^+$ cells isolated using Miltenyi CD4 Microbeads and LS columns (Miltenyi Biotech, Oxford, UK) and resuspended in AIM-V® medium at $2x10^6$ cells/ml.

On day 8, T cell proliferation assays were established whereby $1x10^5$ autologous $CD4^+$ T cells were added to $1x10^4$ humanised or chimeric antibody-loaded DC (ratio of 10:1) in 96 well U-bottomed plates, with AIM-V® medium added to a final volume 200ul/well). On day 14, assay plates were pulsed with 1uCi [3H] (Perkin Elmer, Beaconsfield, UK) per well in 25ul AIMV for 6 hours before harvesting onto filter mats (Perkin Elmer) using a TomTec Mach III (Hamden CT, USA) cell harvester. All antibody preparations were tested in sextuplet cultures. Counts per minute (cpm) for each well were determined by Meltilex™ (Perkin Elmer) scintillation counting on a 1450 Microbeta Wallac Trilux Liquid Scintillation Counter (Perkin Elmer) in paralux, low background counting. Counts per minute for each antibody sample were normalised to the AIM V® medium only control.

For ELISpot assays, ELISpot plates (Millipore, Watford, UK) were coated with 100µl/well IL-2 capture antibody (R&D Systems, Abingdon, UK) in PBS. Plates were then washed twice in PBS, incubated overnight in block buffer (1% BSA (Sigma) in PBS) and washed in AIM V® medium. On day 8, $1x10^5$ autologous $CD4^+$ T cells were added to $1x10^4$ antigen loaded DC (ratio of 10:1) in 96 well ELISpot plates. All antibody preparations were tested in sextuplet cultures. For each donor PBMC, a

negative control (AIM V® medium alone), no cells control and a PHA (10ug/ml) positive control were also included.

After a further 7 day incubation period, ELISpot plates were developed by three sequential washes in dH_2O and PBS prior to the addition of 100µl filtered biotinylated detection antibody (R&D Systems, Abingdon, UK) in PBS/1% BSA. Following incubation at 37°C for 1.5 hour, plates were further washed three times in PBS and 100µl filtered streptavidin-AP (R&D Systems) in PBS/1% BSA was added for 1 hour (incubation at room temperature). Streptavidin-AP was discarded and plates were washed four times in PBS. BCIP/NBT (R&D Systems) was added to each well and incubated for 30 minutes at room temperature. Spot development was stopped by washing the wells and the backs of the wells three times with dH_2O. Dried plates were scanned on an Immunoscan™ Analyser and spots per well (spw) were determined using Immunoscan™ Version 4 software.

For both proliferation and IL-2 ELISpot assays, results were expressed as a Stimulation Index (SI) defined as the ratio of cpm (proliferation assay) or spots (ELISpot assay) for the test antibody against a medium-only control using a threshold of SI equal to or greater than 2 ($SI \geq 2.0$) for positive T cell responses. The data showed that the chimeric 8H5 and chimeric 3B10 antibodies induced T cell responses in 8 or more of the 50 donor PBMCs tested (>=16%) whilst none of the humanised 8H5 or 3B10 antibodies induced T cell responses in more than 2 of 50 donors (<=4%, average 2% +-2%) demonstrating the effectiveness of the humanisation process in removing T cell responses from the V-regions. In parallel, DNA with V-region sequences from the fully human anti-CTLA4 antibodies MDX010 (Ipilimumab) (Keler et al., ibid) and Tremelimumab (Ribas et al., ibid) were synthesised and used to produce recombinant IgG1/kappa forms of these antibodies with methods as detailed in Example 5. NS0-derived preparations of these antibodies were then tested with the same 50 donor PBMCs as above for induction of CD4+ helper T cell responses in

sextuplicate cultures. T cell responses were detected in an average of 4 donors for Ipilimumab (8% +- 2%) and 5 donors for the IgG1/κ version of Tremelimumab (10% +-2%) thus demonstrating that only the humanised anti-CTLA4 antibodies of the present invention, when tested *in vitro* for induction of CD4+ helper T cell responses in 50 human blood samples, were able to give CD4+ T cell responses in <=4% of donors.

EXAMPLE 9 – HUMAN MIXED LYMPHOCYTE REACTION (MLR) MODEL

A mixed lymphocyte reaction assay was used to measure the effect of blocking the CTLA4 pathway on IFN-γ secretion as a measure of human T cell activation. Fresh blood from multiple human donors (obtained from UK National Blood Transfusion Service, Example 8) was diluted 1:1 with PBS/2% human serum and layered on Lymphoprep solution (Nycomed) for centrifugation at 900g. PBMCs were removed from the interface, washed and resuspended in AIM-V medium (Invitrogen). PBMCs generated from different mismatched donor pairs were then combined at a 1:1 ratio and plated in a 96 well plate to provide a total of 2.5×10^5 PBMCs per sample well. PHA (phytohemaglutinin, Sigma Aldrich) was added for a final concentration of 2μg/ml to stimulate proliferation of T-cell populations. Either the lead VH5/VK4 anti-CTLA4 antibody, the MDX010 anti-CTLA4 control antibody (example 8) or an isotype control IgG1 antibody were added to a final concentration of 150μg/ml. 5μg/ml CTLA4-Fc was also used instead of antibody as a control to demonstrate inhibition of IFN-γ secretion. Total final volume per well was 150μl and each antibody was tested five times per donor combination. 96 well plates were incubated under normal culture conditions for 72hrs after which 100 μl supernatant was sampled for measurement of IFN-γ by ELISA (Thermo scientific, ESS0002) following the manufacturer's recommended protocol. From the data in Figure 19, the lead VH5/VK4 antibody showed higher T cell activation than the MDX010 anti-CTLA4 control antibody for all donor combinations with an average increase of >2-fold in T cell activation for VH5/VK4 compared to MDX010.

EXAMPLE 10 - TUMOUR ANIMAL MODEL

A tumour animal model was used for the *in vivo* analysis of anti-human CTLA4 antibodies in inhibiting tumour growth. In the model, MC38 murine colon tumour cells (Corbett et al., (1975) Cancer Res 35:2434-2439, supplied by OncoImmune, Inc., Ann Arbor, USA) were grown in human CTLA4 knock-in mice (OncoImmune, Inc.).

CTLA4 knock-in mice (7-10 weeks old, males and females distributed equally across groups) were injected subcutaneously in the flank with $5x10^5$ MC38 tumour cells in 0.1ml volume. Either the lead VH5/VK4 anti-CTLA4 antibody, MDX010 (Example 8) or an isotype matched control antibody were injected at either 5mg/kg or 10mg/kg doses (dosing volume 10ml/kg) weekly starting the day following tumour cell administration ("Day 2"). Tumour measurements were taken biweekly during the course of the experiment by caliper measurement and tumour size was expressed as the cubic volume (mm^3). Animals were followed either until a tumour volume of 2000 mm^3 was reached or at day 45 after injection of tumour cells. The results shown in Example 19 demonstrate an improved inhibition of tumour growth by the lead VH5/VK4 anti-CTLA4 antibody compared to MDX010.

CLAIMS:

1. An anti-CTLA4 antibody which inhibits the binding of CTLA4 to human B7.

2. An anti CTLA4 antibody of claim 1 which inhibits binding of CTLA4 to human B7.1 and/or human B7.2.

3. An anti-CTLA4 antibody of claim 1 or claim 2 comprising variable regions with at least one, two, three, four or five CDR sequences selected from the group consisting of ;

(i) CDRH1 comprising sequence DYNMD (SEQ ID NO:9)
(ii) CDRH2 comprising sequence NINPNSESTSYNQKFKG (SEQ ID NO: 10)
(iii) CDRH3 comprising sequence DGNRYDAWFAY (SEQ ID NO:11)
(iv) CDRL1 comprising sequence SASSSVTYMH (SEQ ID NO:12);
(v) CDRL2 comprising sequence STSILAS (SEQ ID NO:13) ; and
(vi) CDRL3 comprising sequence QQRTSYPLT (SEQ ID NO:14).

4. An anti-CTLA4 antibody of claim 1 or claim 2 comprising variable regions with at least one, two, three, four or five CDR sequences selected from the group consisting of ;

(i) CDRH1 comprising sequence SYWIN (SEQ ID NO:15)
(ii) CDRH2 comprising sequence RIAPGSGTTYYNEVFKG (SEQ ID NO: 16)
(iii) CDRH3 comprising sequence GDYGSY (SEQ ID NO:17)
(iv) CDRL1 comprising sequence SASSSISYMH (SEQ ID NO:18);
(v) CDRL2 comprising sequence DTSKLAS (SEQ ID NO:19) ; and
(vi) CDRL3 comprising sequence HQRTSYPLT (SEQ ID NO:20).

5. An anti-CTLA4 antibody of claim 1 or claim 2 comprising variable region sequences selected from the group consisting of SEQ ID NOS: 31-35 for the heavy chain variable region in combination with sequences selected from the group consisting of SEQ ID NOS: 36-40 for the light chain variable region.

6. An anti-CTLA4 antibody of claim 1 or claim 2 comprising variable region sequences selected from the group consisting of SEQ ID NOS: 41-45 for the heavy chain variable region in combination with sequences selected from the group consisting of SEQ ID NOS: 46-50 for the light chain variable region.

7. An anti-CTLA4 antibody of claim 6 comprising SEQ ID NO: 45 for the heavy chain variable region in combination with SEQ ID NO: 49 for the light chain variable region.

8. An anti-CTLA4 antibody of any one of claims 1 to 7 which, when tested *in vitro* for induction of CD4+ helper T cell responses in at least 50 human blood samples with a distribution of HLA-DR allotypes from the human population, gives rise to <=4% of T cell responses.

9. The antibody of claims 1 to 8 wherein the variable region sequences are entirely derived from sequences in human antibody variable regions.

10. The antibody of claims 1 to 9 wherein binding to human CTLA4 can block binding to human B7.1 or B7.2 by at least 90%.

11. The antibody of claims 1 to 10 which binds to human CTLA4 with an equilibrium dissociation constant (Kd) of at least 10^{-8}M.

12. The antibody of claims 1-11 which is comprised of variable regions together with a heavy chain constant region of either isotype IgG1, IgG2, IgG3 or IgG4, or a mutated IgG constant region, and a light chain constant region of isotype kappa.

13. The antibody of claim 12 where the human constant regions are IgG1 and kappa.

14. The antibody of claim 12 where the human constant regions are IgG4 and kappa.

15. The antibody of claims 1-11 where the antibody is a scFv or Fab.

16. A multispecific antibody comprising one or more antibodies of claims 1-15.

17. A polynucleotide encoding an antibody of any of claims 1-16.

18. A vector comprising the polynucleotide of claim 17.

19. A vector of claim 18 wherein the vector is an expression vector.

20. A host cell comprising a vector of claims 18 or 19.

21. The host cell of claim 20 wherein the host cell is prokaryotic.

22. The host cell of claim 20, wherein the host cell is eukaryotic.

23. The host cell of claim 22 wherein the host cell is mammalian.

24. A composition comprising an anti-CTLA4 antibody of any of claims 1-16.

25. A composition comprising a polynucleotide of any of claims 17-19.

26. A method for treating a disease including cancer, a cell proliferative disorder, a disease of the central nervous system (CNS), a disease of the blood system, an inflammatory disease, an infectious disease, an allergy, a T-cell related disease, graft versus host disease or host versus graft disease comprising administering an effective amount of an antibody of any one of claims 1 to 16 or a polynucleotide of any of claims 17 to 19 to a subject in need of such treatment.

27. A method for treating a cancer where the cancer is prostate, kidney, colon, lung or breast cancer comprising administering an effective amount of an antibody of any one of claims 1 to 16 or a polynucleotide of any of claims 17 to 19 to a subject in need of such treatment.

28. The method of claims 26 or 27 which further comprises co-administering an effective amount of a chemotherapeutic agent.

29. The method of any of claims 26 to 28 which further comprises co-administering a pharmaceutical carrier including a vaccine.

30. The use of an antibody of any one of claims 1 to 16 in a method for detecting *in vitro* or *in vivo* the presence of human CTLA4 antigen in a sample for diagnosis of a human CTLA4-related disease.

31. An antibody of any one of claims 1 to 16 or a polynucleotide of any one of claims 17 to 19 for use in treating a disease including cancer, a cell proliferative disorder, a disease of the central nervous system (CNS), a disease of the blood system, an inflammatory disease, an infectious disease, an allergy, a T-cell related disease, graft versus host disease or host versus graft disease.

Figure 1:


Binding of murine antibodies to CTLA4-Fc
OD450nm
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0.0001
0.001
0.01
0.1
1
10
[IgG] ug/ml
8H5 1B1
3B10 4F7/1B9
7B9 1A3
2C7 1G10
Irrelevant mIgG

Figure 2:


Competition of mouse hybridoma antibodies against biotinylated B7.1
Binding (%)
140
120
100
80
60
40
20
0
0.001
0.01
0.1
1
10
100
[IgG] ug/ml
7B9-1A3
2C7-1A3
Irrelevant mIgG
8H5 1B1
3B10 4F7 1B9

Figure 3:


Competition of mouse hybridoma antibodies against biotinylated B7.2
Binding (%)
140
120
100
80
60
40
20
0
0.001
0.01
0.1
1
10
100
[IgG] ug/ml
7B9-1A3
2C7-1A3
Irrelevant mIgG
8H5 1B1
3B10 4F7 1B9

Figure 4:


Binding of human (chimeric) IgG1 antibodies to CTLA4-Fc
OD450nm
1.2
1
0.8
0.6
0.4
0.2
0
0.0001
0.001
0.01
0.1
1
10
[IgG] ug/ml
8H5 IgG1
3B10 IgG1
Irrelevant hIgG1

Figure 5:


Competition of human (chimeric) IgG1 antibodies against biotinylated B7.1
Binding (%)
120
100
80
60
40
20
0
0.001
0.01
0.1
1
10
100
[IgG] ug/ml
8H5 IgG1
3B10 IgG1
Irrelevant hIgG1

Figure 6:


Competition of human (chimeric) IgG1 antibodies against biotinylated B7.2
Binding (%)
120
100
80
60
40
20
0
0.001
0.01
0.1
1
10
100
[IgG] ug/ml
8H5 IgG1
3B10 IgG1
Irrelevant hIgG1

Figure 7:


Thymidine Proliferation response (normalised)
Normalised Counts
200
180
160
140
120
100
80
60
40
20
0
0
20
40
60
80
100
120
IgG (ug/ml)
3B10 IgG1
8H5 IgG1
IgG1 Isotype control


Thymidine Proliferation response (normalised)
Normalised Counts
200
180
160
140
120
100
80
60
40
20
0
0
20
40
60
80
100
120
IgG (ug/ml)
3B10 IgG1
8H5 IgG1
IgG1 Isotype control

Figure 8:


pANT17 IgG1 Map
6000
1000
5000
2000
4000
3000
CH3
CH2
CH1
pANT13 Kappa Map
4000
500
3500
1000
3000
1500
2500
2000
Kappa C Domain

Figure 9:

3B10 Hybridoma VH DNA (SEQ ID No. 1)

```
GAGGTCCAGC TGCAACAGTT TGGAGCTGAA CTGGTGAAGC CTGGGGCTTC   50
AGTGAAGATG TCCTGCAAGG CTTCTGGCTA CACATTCACT GACTACAACA  100
TGGACTGGGT GAGGCAGAGC CATGGAAAGA GTCTTGAGTG GATCGGAAAT  150
ATTAATCCTA ACTCTGAGAG TACTAGTTAC AACCAGAAGT TCAAGGGAAA  200
GGCCACATTG ACTGTAGACA AGTCCTCCAG CACAGCCTAC ATGGAGCTCC  250
GCAGCCTGAC ATCTGATGAC ACTGCAGTCT ATTACTGTAC AAGAGACGGG  300
AATAGGTACG ACGCCTGGTT TGCTTACTGG GGCCAAGGGA CTCTGGTCAC  350
TGTCTCCTCA                                              360
```

3B10 Hybridoma VK DNA (SEQ ID No. 2)

```
CAGATTGTTC TCACCCAGTC TCCAGCAATC ATGTCTGCAT CTCCAGGGGA   50
GAAGGTCACC ATGACCTGCA GTGCCAGCTC AAGTGTTACT TACATGCACT  100
GGTTCCAGCA GAAGCCAGGC ACTTCTCCCA AACTCTGGAT TTATAGCACA  150
TCCATCCTGG CTTCTGGAGT CCCTGCTCGC TTCAGTGGCA GTGGATCTGG  200
GACCTCTTAC TCTCTCACAA TCAGCCGAAT GGAGGCTGAA GATGCTGCCA  250
CTTATTACTG CCAGCAAAGG ACTAGTTACC CGCTCACGTT CGGTACTGGG  300
ACCAAGCTGG AGCTGAAA                                     318
```

Figure 10:

8H5 Hybridoma VH DNA (SEQ ID No. 5)

```
CAGGTCCAGC TGCAACAGTC TGGAGATGAT CTGGTAAAGC CTGGGGCCTC   50
AGTGAAGCTG TCCTGCAAGG CTTCTGGCTA CACCTTCACC AGCTACTGGA  100
TTAACTGGAT AAAACAGAGG CCTGGACAGG GCCTTGAGTG GATAGGACGT  150
ATTGCTCCTG GAAGTGGTAC TACTTACTAC AATGAAGTGT TCAAGGGCAA  200
GGCAACACTG ACTGTAGACA AATATTCCAG CACAGCCTAC ATTCAGCTCA  250
GCAGCCTGTC ATCTGAGGAC TCTGCTGTCT ATTTCTGTGC AAGAGGGGAC  300
TATGGTTCTT ACTGGGGCCA AGGGACTCTG GTCACTGTCT CCTCA       345
```

8H5 Hybridoma VK DNA (SEQ ID No. 6)

```
CAAATTGTTC TCACCCAGTC TCCAGCAATC ATGTCTGCAT CTCCAGGGGA   50
GAAGGTCACC ATGACCTGCA GTGCCAGCTC AAGTATAAGT TACATGCACT  100
GGTTCCAGCA GAAGCCAGGC ACCTCCCCCA AAAGATGGAT TTATGACACA  150
TCCAAACTGG CTTCTGGAGT CCCTGCTCGC TTCAGTGGCA GTGGGTCTGG  200
GACCTCTTAT TCTCTCACAA TCAACAGCAT GGAGGCTGAA GATGCTGCCA  250
CTTATTACTG CCATCAGCGG ACTAGTTACC CACTCACGTT CGGTGCTGGG  300
ACCAAGCTGG AGCTGAAA                                    318
```

Figure 11:

3B10 Hybridoma VH Amino Acid (SEQ ID No. 3)



3B10 Hybridoma VK Amino Acid (SEQ ID No. 4)



Figure 12:

8H5 Hybridoma VH Amino Acid (SEQ ID No. 7)



8H5 Hybridoma VK Amino Acid (SEQ ID No. 8)



Figure 13:

Humanised 3B10 variant VH amino acid sequences (SEQ ID Nos 3 and 31 to 35)



Figure 14:

Humanised 3B10 variant VK amino acid sequences (SEQ ID Nos 4 and 36 to 40)



Figure 15:

Humanised 8H5 variant VH amino acid sequences (SEQ ID Nos 7 and 41 to 45)



Figure 16:

Humanised 8H5 variant VK amino acid sequences (SEQ ID Nos 8 and 46-50)

	1									10									20		23	24								30			33	35				40
																						CDR 1															
mouse VK (SEQ ID No. 8)	Q	I	V	L	T	Q	S	P	A	I	M	S	A	S	P	G	E	K	V	T	M	T	C	S	A	S	S	S	I	S	Y	M	H	W	F	Q	Q	K	P
VK1 protein (SEQ ID No. 46)	Q	I	V	L	T	Q	S	P	A	I	L	S	L	S	P	G	E	R	A	T	M	S	C	S	A	S	S	S	I	S	Y	M	H	W	F	Q	Q	R	P
VK2 protein (SEQ ID No. 47)	Q	I	V	L	T	Q	S	P	A	T	L	S	L	S	P	G	E	R	A	T	L	S	C	S	A	S	S	S	I	S	Y	M	H	W	F	Q	Q	R	P
VK3 protein (SEQ ID No. 48)	E	I	V	L	T	Q	S	P	A	T	L	S	L	S	P	G	E	R	A	T	L	S	C	S	A	S	S	S	I	S	Y	M	H	W	F	Q	Q	R	P
VK4 protein (SEQ ID No. 49)	E	I	V	L	T	Q	S	P	A	T	L	S	L	S	P	G	E	R	A	T	L	S	C	S	A	S	S	S	I	S	Y	M	H	W	F	Q	Q	R	P
VK5 protein (SEQ ID No. 50)	E	I	V	L	T	Q	S	P	A	T	L	S	L	S	P	G	E	R	A	T	M	S	C	S	A	S	S	S	I	S	Y	M	H	W	F	Q	Q	R	P

	41							49	50						56	57			60											70							79
									CDR 2																													
mouse VK	G	T	S	P	K	R	W	I	Y	D	T	S	K	L	A	S	G	V	P	A	R	F	S	G	S	G	S	G	T	S	Y	S	L	T	I	N	S	M	E
VK1 protein	G	Q	S	P	K	R	W	I	Y	D	T	S	K	L	A	S	G	V	P	A	R	F	S	G	S	G	S	G	T	S	Y	T	L	T	I	S	S	L	E
VK2 protein	G	Q	S	P	R	R	W	I	Y	D	T	S	K	L	A	S	G	V	P	A	R	F	S	G	S	G	S	G	T	S	Y	T	L	T	I	S	S	L	E
VK3 protein	G	Q	S	P	R	R	W	I	Y	D	T	S	K	L	A	S	G	V	P	A	R	F	S	G	S	G	S	G	T	D	Y	T	L	T	I	S	S	L	E
VK4 protein	G	Q	S	P	R	R	W	I	Y	D	T	S	K	L	A	S	G	V	P	A	R	F	S	G	S	G	S	G	T	D	Y	T	L	T	I	S	S	L	E
VK5 protein	G	Q	S	P	R	R	L	I	Y	D	T	S	K	L	A	S	G	V	P	A	R	F	S	G	S	G	S	G	T	D	Y	T	L	T	I	S	S	L	E

	80							88	89	90					97	98		100							106A
									CDR 3																
mouse VK	A	E	D	A	A	T	Y	Y	C	H	Q	R	T	S	Y	P	L	T	F	G	A	G	T	K	L	E	L	K
VK1 protein	A	E	D	F	A	T	Y	Y	C	H	Q	R	T	S	Y	P	L	T	F	G	Q	G	T	K	L	E	I	K
VK2 protein	A	E	D	F	A	T	Y	Y	C	H	Q	R	T	S	Y	P	L	T	F	G	Q	G	T	K	L	E	I	K
VK3 protein	A	E	D	F	A	T	Y	Y	C	H	Q	R	T	S	Y	P	L	T	F	G	Q	G	T	K	L	E	I	K
VK4 protein	P	E	D	F	A	T	Y	Y	C	H	Q	R	T	S	Y	P	L	T	F	G	Q	G	T	K	L	E	I	K
VK5 protein	P	E	D	F	A	T	Y	Y	C	H	Q	R	T	S	Y	P	L	T	F	G	Q	G	T	K	L	E	I	K

Figure 17:


Competition ELISA - Sample vs bio h8H5 IgG1
Binding (%)
[IgG] ug/ml
h8H5 Parent IgG1
Irrel IgG1
h8H5 IgG1 VH1/VK1
h8H5 IgG1 VH4/VK3
h8H5 IgG1 VH4/VK4
Competition ELISA - Sample vs bio h8H5 IgG1
Binding (%)
[IgG] ug/ml
h8H5 Parent IgG1
Irrel IgG1
h8H5 IgG1 VH4/VK5
h8H5 IgG1 VH5/VK3
h8H5 IgG1 VH5/VK4
Competition ELISA - Sample vs bio h8H5 IgG1
Binding (%)
[IgG] ug/ml
h8H5 Parent IgG1
Irrel IgG1
h8H5 IgG1 VH5/VK5

Figure 18: Human Mixed Lymphocyte Reaction Model



Figure 19: Tumour Animal Model



Sequence	Name-Pool
ATGRASTTSKGGYTMARCTKGRTTT	MuIgV$_H$5'-A
ATGRAATGSASCTGGGTYWTYCTCTT	MuIgV$_H$5'-B
ATGGACTCCAGGCTCAATTTAGTTTTCCT	MuIgV$_H$5'-C
ATGGCTGTCYTRGBGCTGYTCYTCTG	MuIgV$_H$5'-C
ATGGVTTGGSTGTGGAMCTTGCYATTCCT	MuIgV$_H$5'-C
ATGAAATGCAGCTGGRTYATSTTCTT	MuIgV$_H$5'-D
ATGGRCAGRCTTACWTYYTCATTCCT	MuIgV$_H$5'-D
ATGATGGTGTTAAGTCTTCTGTACCT	MuIgV$_H$5'-D
ATGGGATGGAGCTRTATCATSYTCTT	MuIgV$_H$5'-E
ATGAAGWTGTGGBTRAACTGGRT	MuIgV$_H$5'-E
ATGGRATGGASCKKIRTCTTTMTCT	MuIgV$_H$5'-E
ATGAACTTYGGGYTSAGMTTGRTTT	MuIgV$_H$5'-F
ATGTACTTGGGACTGAGCTGTGTAT	MuIgV$_H$5'-F
ATGAGAGTGCTGATTCTTTTGTG	MuIgV$_H$5'-F
ATGGATTTTGGGCTGATTTTTTTTATTG	MuIgV$_H$5'-F
CCAGGGRCCARKGGATARACIGRTGG	MuIgGV$_H$3'-2
ATGRAGWCACAKWCYCAGGTCTTT	MuIgkV$_L$5'-A
ATGGAGACAGACACACTCCTGCTAT	MuIgkV$_L$5'-B
ATGGAGWCAGACACACTSCTGYTATGGGT	MuIgkV$_L$5'-C
ATGAGGRCCCCTGCTCAGWTTYTTGGIWTCTT	MuIgkV$_L$5'-D
ATGGGCWTCAAGATGRAGTCACAKWYYCWGG	MuIgkV$_L$5'-D
ATGAGTGTGCYCACTCAGGTCCTGGSGTT	MuIgkV$_L$5'-E
ATGTGGGGAYCGKTTTYAMMCTTTTCAATTG	MuIgkV$_L$5'-E
ATGGAAGCCCCAGCTCAGCTTCTCTTCC	MuIgkV$_L$5'-E
ATGAGIMMKTCIMTTCAITTCYTGGG	MuIgkV$_L$5'-F
ATGAKGTHCYCIGCTCAGYTYCTIRG	MuIgkV$_L$5'-F
ATGGTRTCCWCASCTCAGTTCCTTG	MuIgkV$_L$5'-F
ATGTATATATGTTTGTTGTCTATTTCT	MuIgkV$_L$5'-F
ATGAAGTTGCCTGTTAGGCTGTTGGTGCT	MuIgkV$_L$5'-G
ATGGATTTWCARGTGCAGATTWTCAGCTT	MuIgkV$_L$5'-G
ATGGTYCTYATVTCCTTGCTGTTCTGG	MuIgkV$_L$5'-G
ATGGTYCTYATVTTRCTGCTGCTATGG	MuIgkV$_L$5'-G
ACTGGATGGTGGGAAGATGGA	MuIgkV$_L$3'-1

Table 1

Sequence	Name
ctgttgctacgcgtgtccactccGAGGTCCAGCTGCAACAG	3B10 VH 5'
ctgccccagaaagcttaccTGAGGAGACAGTGACCAGAG	3B10 VH 3'
ggctcccaggcgcgcgatgtCAGATTGTTCTCACCCAGTC	3B10 VK 5'
tagaattgcgggatccaactgaggaagcaaagtttaaattctactcacgTTTCAGCTCCAGCTTGGTC	3B10 VK 3'
ctgttgctacgcgtgtccactccCAGGTCCAGCTGCAACAG	8H5 VH 5'
ctgccccagaaagcttaccTGAGGAGACAGTGACCAGAG	8H5 VH 3'
ggctcccaggcgcgcgatgtCAAATTGTTCTCACCCAGTCTC	8H5 VK 5'
tagaattgcgggatccaactgaggaagcaaagtttaaattctactcacgTTTCAGCTCCAGCTTGGTCC	8H5 VK 3'

Table 2

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2012/054144

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K16/28
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/086459 A1 (MEDAREX INC [US]; DAVIS THOMAS [US]; KELER TIBOR [US]; GRAZIANO ROBERT) 23 October 2003 (2003-10-23) example 4 -----	1,2

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
12 April 2012	24/04/2012

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Vadot, Pierre

1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2012/054144

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03086459 A1	23-10-2003	AU 2003234736 A1	27-10-2003
		AU 2008255203 A1	08-01-2009
		BR 0309254 A	01-03-2005
		CA 2481207 A1	23-10-2003
		CN 1652820 A	10-08-2005
		EP 1503794 A1	09-02-2005
		JP 2005529873 A	06-10-2005
		MX PA04010013 A	13-12-2004
		NZ 536420 A	30-04-2008
		WO 03086459 A1	23-10-2003